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The serum concentrations of amino-terminal procol- 
lagen type III and carboxy-terminal procollagen 
type l-derived peptides, which have been proposed 
as useful markers of the tissue synthesis of collagen 
types Ill and type I, respectively, were abnormally 
increased in patients with essential hypertension 
and became normal after angiotensin-converting 
enzyme (ACE) inhibition. An association was found 
between baseline serum concentrations of these 
peptides and left ventricular hypetirophy, diastolic 
dysfunction, and ventricular arrhythmias in hyper- 
tensive patients. On the other hand, increased se- 
rum concentration of the carboxy-terminal procolla- 
gen type l-derived peptide was found in spon- 
taneously hypertensive rats compared with normo- 
tensive Wistar-Kyoto control mts. An association 
was found between the serum concentmtion of this 
peptide and the extent of myocardial fibrosis and 
the hydroxyproline concentmtion in the left ventricle 
of spontaneously hypertensive rats. It is proposed 
that procollagen-derived peptides in serum may be 
markers of exaggerated collagen tissue synthesis 
involved in hypertensive myocardial fibrosis. 
(Am J Cardiol 1995; 76: 14D-17D) 
A significant increase in fibrillar collagen content has been observed in the cardiac ventricles of both animals1-7 and hu- 
mans8-l2 with arterial hypertension. This myocar- 
dial fibrosis is accomplished by alterations in colla- 
gen synthesis and degradation and by fibroblast 
proliferation.r3J4 Hemodynamic and nonhemody- 
anmic factors may participate in the development 
of myocardial fibrosis that occurs in hyperten- 
sion.15,16 ,As shown experimentally3J7 and clini- 
cally,r8 a rise in collagen content adversely raises 
myocardial stiffness and promotes abnormalities of 
cardiac function. In addition, it has been demon- 
strated that ventricular arrhythmias in hyperten- 
sive patients are related to the degree of myocar- 
dial’ fibrosis.r9 Although some antihypertensive 
agents, such as minoxidil, hydralazine, or hydrochlo- 
rothiazide, have failed to show any significant 
effect on myocardial fibrosis, others, such as angio- 
tensin-converting enzyme (ACE) inhibitors, cal- 
cium antagonists, or aldosterone antagonists, have 
demonstrated profound effects on either preven- 
tion or regression of myocardial fibrosis.20 
Although cardiac biopsies are reliable for mea- 
suring myocardial fibrosis,10J1J8,21 it seems neces- 
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sat-y to develop noninvasive methods that indicate 
the presence of myocardial fibrosis in hypertension 
(i.e., biochemi,cal markers of collagen synthesis). 
This article is based’on the proposal of a biochemi- 
cal method ‘to assess indirectly the myocardial 
synthesis and deposition of fibrillar collagen. 
A BIOCHEMICAL APPROACH TO THE 
ASSESSMENT OF THE CARDIAC 
SYNTHESIS OF FIBRUAR COLLAGEN 
Collagen types III and I are synthesized as 
procollagens with a small amino-terminal and a 
larger carboxy-terminal propeptide. Once secreted 
into the extracellular space, the propeptides are 
removed by specific endopeptidases, thus allowing 
integration of the rigid collagen triple helix into the 
growing fibril. ** The procollagen type III amino- 
terminal peptide (PIIIP) formed during this pro- 
cess is released into the blood. The serum concen- 
tration of PIIIP has been proposed as a useful 
marker of collagen type III synthesis.23 This is 
supported by a diversity of clinical observations 
demonstrating that high serum levels of the pep- 
tides reflect ongoing tissue fibrosis.2428 
The procollagen type I carboxy-terminal pep- 
tide (PIP) is cleaved off procollagen type I during 
the synthesis of the fibril forming collagen type I. In 
contrast to PIIIP, PIP is completely removed from 
its procollagen precursor during the extracellular 
processing of the collagen type I,** thus offering the 
theoretical advantage of directly reflecting fibrogen- 
esis. This has been confirmed in studies conducted 
in patients with different clinical conditions.29-31 
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Therefore, we investigated the serum concentra- 
tions of PIP and PIIIP in different clinical and 
experimental studies to assess the intensity of the 
fibrogenic process in patients with essential hyper- 
tension and in rats with spontaneous hypertension. 
In addition, the relations between serum concentra- 
tions of the 2 peptides and several parameters of 
left ventricular anatomy, structure, biochemistry, 
and function were analyzed to delineate the value 
of these peptides as potential markers of ventricu- 
lar fibrosis in hypertension. 
STUDIES ON SERUM PEPTIDES OF 
COLLAGEN SYNTHESIS IN ARTERIAL 
HYPERTENSION 
Clinical studies: In a previous study32 we deter- 
mined, by specific radioimmunoassay, the serum 
concentrations of PIIIP in 24 patients with essen- 
tial hypertension who had never been treated and 
in 30 normotensive control subjects. None of the 
subjects exhibited abnormalities suggestive of con- 
ditions associated with elevated serum PIIIP con- 
centrations (chronic liver disease, pulmonary fibro- 
sis, rheumatoid arthritis, extensive wounds, acute 
myocardial infarction). 
As shown in Figure 1, serum PIIIP was higher in 
hypertensive patients than in control subjects 
(11.20 f 0.76 vs 8.47 +- 0.77 rig/ml, mean rl: SEM, 
p < 0.01). A direct correlation was found between 
serum PIIIP and plasma renin activity in the group 
of hypertensive patients. In addition, serum PIIIP 
was correlated inversely with maximal early trans- 
mitral flow velocity measured during diastole by 
Doppler echocardiography in the group of hyper- 
tensive patients, 
Serum concentrations of PIIIP were measured 
in 15 patients after receiving the ACE inhibitor 
lisinopril (10-20 mg once daily) for 6 months. The 
serum PIIIP concentrations decreased significantly 
in these patients (11.76 +- 0.84 vs 8.47 -+ 0.66 ng/ 
ml; p <O.Ol; Figure 1). Blood pressure became 
normal,after treatment with lisinopril. Echocardio- 
graphic parameters assessing left ventricular mass 
were diminished after the treatment period. Trends 
toward normalization of diastolic filling param- 
eters after treatment did not attain statistical 
significance. 
In another study we measured serum PIP in 50 
patients with essential hypertension who had never 
been treated and in 30 normotensive control sub- 
jects.33 Serum PIP was measured by specific radio- 
immunoassay. Conditions associated with elevated 
serum concentrations of PIP (alcoholic liver dis- 
ease, metabolic bone disease) were excluded after 
a complete medical examination. Measurements 
were repeated in 43 hypertensive patients after 6 
months of treatment with lisinopril (lO-20 mg once 
daily). 
Baseline serum concentrations of PIP were 
increased in hypertensive patients compared with 
normotensive subjects (139 + 6 vs 108 +- 6 kg/L; 
p <O.OOl; Figure 2). Serum PIP was correlated 
directly with the left ventricular mass index in the 
group of hypertensive patients. In addition, serum 
PIP concentrations increased in parallel with the 
increase in the Lown-Wolf grade of ventricular 
arrhythmias in the group of hypertensive patients. 
In treated patients blood pressure became nor- 
mal and there was a regression of left ventricular 
mass index and a diminution in the number of daily 
ventricular extrasystoles. Serum PIP concentra- 
tions decreased to normal values in patients treated 
with lisinopril(ll1 + 5 vs 108 5 6 kg/L; p < 0.001; 
Figure 2). 
Experimental study: In a pilot study, we evalu- 
ated serum PIP concentrations in 7 36-week-old 
male spontaneously hypertensive rats with estab- 
lished left ventricular hypertrophy. Specific radio- 
immunoassay was used to measure serum PIP in 
rats. The amount of left ventricular collagen was 
evaluated by measuring the hydroxyproline concen- 
tration. The collagen-specific stain, Masson’s tri- 
chrome, was used to evaluate the presence and 
intensity of interstitial and perivascular fibrosis of 
the left ventricle. 
In spontaneously hypertensive rats compared 
with 7 age- and sex-matched Wistar-Kyoto normo- 
tensive control rats we found: (1) an increase in 
hydroxyproline concentration (1.05 2 0.03 vs 
0.84 + 0.05 m/g dry weight/100 g body weight; 
p ~0.05; Figure 3); and (2) an increase in serum 
PIP (10.31 + 0.58 vs 8.25 -t 0.59 &L, p < 0.05; 
Figure 4). 
All the spontaneously hypertensive rats exhib- 
ited severe interstitial and perivascular fibrosis. 
The absence of pathologic myocardial fibrosis was 
seen in 6 normotensive rats. One Wistar-Kyoto rat 
exhibited mild interstitial fibrosis. 
COMMENTS 
The findings of the studies show an increase in 
serum concentrations of PIIIP and PIP in patients 
with essential hypertension and in spontaneously 
hypertensive rats. Elevated serum PIIIP and PIP 
may be markers of increased collagen type III and 
type I synthesis in arterial hypertension. 
The question arises as to whether the measure- 
ment of PIIIP and PIP accurately reflects tissue 
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fibrillogenesis. In this regard, in experiments of 
quantification of fibroproliferative reactions in situ, 
it has been shown that the PIIIP and the PIP assays 
reflect ongoing collagen synthesis. In fact, when 
the expression of procollagen type III and procolla- 
gen type I is induced, as during wound healing and 
other repair processes, 34,35 the local concentrations 
of the PIIIP and the PIP antigens in interstitial 
fluid increase dramatically, This is in agreement 
with a number of clinical observations showing that 
the circulating levels of the 2 peptides correlate 
well with ongoing tissue fibrosis.243i 
We are aware that by measuring serum procolla- 
gen-derived peptides we assess the formation of 
B A 
NT HT I 
FIGURE 1. Serum concentrations of procollagen type III 
amino-terminal peptide (PIIIP) in normotensives (NT) and 
essential hypertensives (HT) Before (B) and after (A) treat- 
ment. *p co.01 compared with NT; **p <O.Ol compared 
with HT Before treatment. 
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FIGURE 2. Serum concentrations of procollagen type I car- 
boxy-terminal peptide (PIP) in normotensives (NT) and es- 
sential hypertensives (HT) Before (B) and after (A) treatment. 
*p ~0.001 compared with NT; **p ~0.001 compared with 
HT Before treatment. 
fibrillar collagen but not its degradation. Since 
collagen degradation is also altered in arterial 
hypertension, l3 additional studies are necessary to 
assess in a more complete way collagen metabolism 
in hypertension. 
The effects of lisinopril on the serum concentra- 
tions of the 2 peptides in hypertensive patients 
suggest that the rerun-angiotensin-aldosterone sys- 
tem may participate in the excessive synthesis of 
collagen types III and I in essential hypertension. 
This is in agreement with the observation that in 
spontaneously hypertensive rats with left ventricular 
hypertrophy and fibrosis of the cardiac interstitium, 
lisinopril reversed fibrous tissue accumulation.36 
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FIGURE 3. Hydroxyproline concentration in normotensive 
Wistar-Kyoto rats (WKV) and spontaneously hypertensive 








FIGURE 4. Serum concentrations of procollagen type I car- 
boxy-terminal peptide (PIP) in normotensive Wistar-Kyoto 
rats (WKY) and spontaneously hypertensive rats (SHR). 
*p ~0.05 compared with WKY. 
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The relations observed between serum PIIIP 
and PIP and parameters of mass, function, and 
electrical activity of the left ventricle suggest that 
circulating procollagen-derived peptides may re- 
flect ongoing myocardial fibrosis in essential hyper- 
tension. However, because no cardiac biopsies 
were performed in the clinical studies mentioned 
here, the cardiac origin of the 2 peptides remains 
speculative, and other extracardiac sources de- 
serve to be considered. 
In this regard, our finding that serum PIP is 
increased in spontaneously hypertensive rats with 
fibrosis of the left ventricle due to an excess of 
collagen deposition serves to reinforce the role of 
this peptide as a potential serum marker of myocar- 
dial collagen type I synthesis in hypertension. 
In summary, the findings presented here permit 
us to propose that serum procollagen peptide 
measurements may provide indirect diagnostic in- 
formation on the myocardial fibrosis associated 
with arterial hypertension. Histopathologic studies 
of the left ventricle of patients with arterial hyper- 
tension should be carried out to confirm or reject 
this hypothesis. 
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